Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

by Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon
Published 2021-08-01

Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes

by Suzanne V. Arnold, Kensey Gosch, Nathan D. Wong, Vittal Hejjaji, Abhinav Goyal, Lawrence A. Leiter, Mikhail Kosiborod
Published 2020-07-01

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

by Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J. L. Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl
Published 2021-03-01

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

by Jordi Real, Bogdan Vlacho, Emilio Ortega, Joan Antoni Vallés, Manel Mata-Cases, Esmeralda Castelblanco, Eric T. Wittbrodt, Peter Fenici, Mikhail Kosiborod, Dídac Mauricio, Josep Franch-Nadal
Published 2021-07-01

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study

by Jesús Medina, Peter Fenici, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Iichiro Shimomura, Mikhail Kosiborod, Hungta Chen, Andrew Cooper, Brenda Bongaerts, Bernard H Charbonnel, Marilia Gomes, Marina Shestakova
Published 2021-08-01

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme

by Peter Fenici, Niklas Hammar, Linong Ji, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Wolfgang Rathmann, Iichiro Shimomura, Marilia B Gomes, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Hungta Chen, Javier Cid-Ruzafa
Published 2020-08-01

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)

by Mikhail Kosiborod, Marilia B. Gomes, Antonio Nicolucci, Stuart Pocock, Wolfgang Rathmann, Marina V. Shestakova, Hirotaka Watada, Iichiro Shimomura, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Niklas Hammar, Filip Surmont, Fengming Tang, Kamlesh Khunti, for The DISCOVER investigators
Published 2018-11-01

Type 2 diabetes and heart failure: insights from the global DISCOVER study

by Suzanne V. Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Javier Cid‐Ruzafa, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Gabriela Luporini‐Saraiva, Jesús Medina, Antonio Nicolucci, Larisa Ramirez, Marina V. Shestakova, Iichiro Shimomura, Filip Surmont, Fengming Tang, Jiten Vora, Hirotaka Watada, Mikhail Kosiborod, the DISCOVER investigators
Published 2021-04-01

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

by Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S. P. Lam, Su-Yen Goh, Chern-En Chiang, Jonathan E. Shaw, Matthew A. Cavender, Navdeep Tangri, Josep Franch-Nadal, Reinhard W. Holl, Marit E. Jørgensen, Anna Norhammar, Johan G. Eriksson, Francesco Zaccardi, Avraham Karasik, Dianna J. Magliano, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, the CVD-REAL Investigators and Study Group
Published 2021-07-01